
Ask a doctor about a prescription for OLMESARTAN AUROVITAS 10 mg FILM-COATED TABLETS
Package Leaflet: Information for the User
Olmesartan Aurovitas 10 mg film-coated tablets EFG
Olmesartan medoxomil
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Olmesartan Aurovitas belongs to a group of medicines called angiotensin II receptor antagonists. They lower blood pressure by relaxing blood vessels.
Olmesartan Aurovitas is used to treat high blood pressure (also known as hypertension) in adults and in children and adolescents from 6 to less than 18 years of age. High blood pressure can damage blood vessels in organs such as the heart, kidneys, brain, and eyes. In some cases, this can lead to a heart attack, heart failure, or kidney failure, stroke, or blindness. Usually, high blood pressure does not present symptoms. It is important to control your blood pressure to avoid damage.
High blood pressure can be controlled with medicines such as Olmesartan Aurovitas tablets. Your doctor may also have recommended that you make some changes to your lifestyle to help lower your blood pressure (e.g., lose weight, stop smoking, reduce alcohol consumption, and reduce the amount of salt in your diet). Your doctor may also have recommended that you exercise regularly, such as walking or swimming. It is important to follow your doctor's advice.
Do not takeOlmesartan Aurovitas
Warnings and precautions
Tell your doctor before you start taking Olmesartan Aurovitas.
Tell your doctorif you are taking any of the following medicines to treat high blood pressure:
Your doctor may check your kidney function, blood pressure, and blood electrolyte levels (e.g., potassium) at regular intervals.
See also the information under the heading “Do not take Olmesartan Aurovitas”.
Tell your doctorif you have any of the following health problems:
Contact your doctor if you have severe, persistent diarrhea that causes significant weight loss. Your doctor will assess your symptoms and decide how to proceed with your blood pressure treatment.
As with any other medicine that lowers blood pressure, excessive lowering of blood pressure in patients with impaired blood flow to the heart or brain may cause a heart attack or stroke. Therefore, your doctor will closely monitor your blood pressure.
You should inform your doctor if you think you are (or might become) pregnant. Olmesartan is not recommended during pregnancy, and it should not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if taken at this stage (see section Pregnancy).
Consult your doctor if you experience abdominal pain, nausea, vomiting, or diarrhea after taking olmesartan. Your doctor will decide whether to continue treatment. Do not stop taking olmesartan on your own.
Black patients
As with other similar medicines, the blood pressure-lowering effect of olmesartan is somewhat smaller in black patients.
Elderly patients
If you are over 65 years of age and your doctor decides to increase your dose of olmesartan medoxomil to 40 mg daily, then you need your doctor to check your blood pressure regularly to ensure that your blood pressure does not become too low.
Children and adolescents
Olmesartan medoxomil has been studied in children and adolescents. For more information, consult your doctor. Olmesartan medoxomil is not recommended for use in children under 1 year of age, and it should not be used in children from 1 year to less than 6 years of age, as there is no experience with it.
Taking Olmesartan Aurovitas with other medicines
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
In particular, tell your doctor or pharmacist about any of the following medicines:
It may be necessary for your doctor to change your dose and/or take other precautions:
If you are taking an angiotensin-converting enzyme inhibitor (ACE inhibitor) or aliskiren (see also the information under the headings “Do not take Olmesartan Aurovitas” and “Warnings and precautions”).
Taking Olmesartan Aurovitas with food and drink
Olmesartan Aurovitas can be taken with or without food.
Pregnancy and breastfeeding
Pregnancy
You should inform your doctor if you are pregnant, think you might be pregnant, or plan to become pregnant. Your doctor will normally advise you to stop taking olmesartan before you become pregnant or as soon as you know you are pregnant, and will advise you to take another medicine instead. Olmesartan should not be used during pregnancy, and it must not be taken after the third month of pregnancy, as it may cause serious harm to your baby if taken after this point.
Breastfeeding
Tell your doctor if you are breastfeeding or about to start breastfeeding. Olmesartan is not recommended during breastfeeding. Your doctor may choose another treatment if you want to continue breastfeeding, especially if your baby is newborn or premature.
If you are pregnant or breastfeeding, think you may be pregnant, or plan to become pregnant, ask your doctor or pharmacist for advice before taking this medicine.
Driving and using machines
You may feel dizzy or faint while being treated for high blood pressure. If this happens, do not drive or use machines until the symptoms have disappeared. Consult your doctor.
Olmesartan Aurovitas contains lactose
This medicine contains lactose (a type of sugar). If your doctor has told you that you have an intolerance to some sugars, consult your doctor before taking this medicine.
Follow exactly the instructions of administration of this medicine given to you by your doctor. If you are not sure, consult your doctor or pharmacist again.
The recommended initial dose is 1 tablet of 10 mg per day. If your blood pressure is not adequately controlled, your doctor may increase the dose to 20 mg or 40 mg per day or prescribe additional treatment.
In patients with mild to moderate kidney failure, the maximum dose is 20 mg once daily.
The tablets can be taken with or without food. Take the tablets with a sufficient amount of water (e.g., a glass). If possible, take your dose at the same time each day, e.g., at breakfast time.
Children and adolescents from 6 to less than 18 years of age:
The recommended initial dose is 10 mg once daily. If the patient's blood pressure is not adequately controlled, the doctor may decide to change the dose to 20 or 40 mg once daily. In children who weigh less than 35 kg, the dose will not exceed 20 mg once daily.
If you take more Olmesartan Aurovitas than you should
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, telephone: 91 562 04 20, indicating the medicine and the amount taken. It is recommended to take the package and the package leaflet of the medicine to the healthcare professional.
If you forget to take Olmesartan Aurovitas
If you forget to take a dose, take your usual dose the next day as usual. Do not take a double dose to make up for forgotten doses.
If you stop taking Olmesartan Aurovitas
It is important to continue taking olmesartan unless your doctor tells you to stop.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them. If they do occur, they are often mild and do not require treatment to be stopped.
The following side effects may be serious, although they are rare:
In rare cases (may affect up to 1 in 1,000 people), the following allergic reactions have been reported, which can affect the whole body:
During treatment with olmesartan, inflammation of the face, mouth, and/or larynx, along with itching and skin rash, may occur. If this happens to you, stop taking olmesartan and consult your doctor immediately.
Rarely (but more frequently in elderly people), olmesartan may cause a pronounced drop in blood pressure in susceptible individuals or as a result of an allergic reaction. This can cause fainting or severe dizziness. If this happens to you, stop taking olmesartan, consult your doctor immediately, and remain lying down.
Frequency not known (cannot be estimated from the available data)
If you experience yellowing of the whites of the eyes, dark urine, itching of the skin, even if you started treatment with olmesartan a long time ago, contact your doctor immediately, who will assess your symptoms and decide how to proceed with your blood pressure treatment.
These are other known side effects of olmesartan:
Common side effects(may affect up to 1 in 10 people):
Dizziness, headache, nausea, indigestion, diarrhea, stomach pain, gastroenteritis, tiredness, sore throat, nasal congestion and discharge, bronchitis, flu-like symptoms, cough, pain, chest pain, back, bone, or joint pain, urinary tract infection, swelling of the ankles, feet, legs, hands, or arms, blood in the urine.
Some changes in the results of certain blood tests have also been observed: increased levels of fat (hypertriglyceridemia), increased levels of uric acid (hyperuricemia), increased urea levels in the blood, increases in liver and muscle function test values.
Uncommon side effects(may affect up to 1 in 100 people):
Rapid allergic reactions that can affect the whole body and may cause breathing problems, as well as a rapid drop in blood pressure that can lead to fainting (anaphylactic reactions), facial inflammation, dizziness, vomiting, weakness, feeling unwell, muscle pain, skin rash, allergic skin rash, itching, exanthema (skin rash), skin swelling (hives), angina pectoris (chest pain or discomfort).
In blood tests, a decrease in the number of a type of blood cell called platelets (thrombocytopenia) has been observed.
Rare side effects(may affect up to 1 in 1,000 people):
Intestinal angioedema: swelling in the intestine that occurs with symptoms such as abdominal pain, nausea, vomiting, and diarrhea.
Lack of energy, muscle cramps, decreased kidney function, kidney failure.
Some changes in the results of blood tests have also been observed, including increased potassium levels (hyperkalemia) and increased levels of compounds related to kidney function.
Other side effects in children and adolescents:
In children, similar side effects have been observed as in adults. However, dizziness and headache have been observed more frequently in children, and nosebleeds are a common side effect observed only in children.
Reporting of side effects:
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the Spanish Medicines Agency's website: www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date is the last day of the month shown.
Store below 30°C.
Medicines should not be disposed of via wastewater or household waste. Return any unused medicine to a pharmacy for proper disposal. If you are unsure, ask your pharmacist how to dispose of unused medicines. This will help protect the environment.
Composition of Olmesartan Aurovitas
Core of the tablet:lactose monohydrate, microcrystalline cellulose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, magnesium stearate.
Coating of the tablet:hydroxypropylcellulose, titanium dioxide (E171), talc, red iron oxide (E172), yellow iron oxide (E172).
Appearance of the product and contents of the pack
Film-coated tablets, biconvex, round, orange, with the mark “K” on one face and “17” on the other.
Olmesartan Aurovitas is available in blister packs of Polyamide/Aluminum/PVC-Aluminum.
Package sizes: 14, 28, and 56 film-coated tablets.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder:
Aurovitas Spain, S.A.U.
Avda. de Burgos, 16-D
28036 Madrid
Spain
Manufacturer:
APL Swift Services (Malta) Limited
HF26, Hal Far Industrial Estate, Hal Far
Birzebbugia, BBG 3000
Malta
This medicine is authorized in the Member States of the European Economic Area under the following names:
Spain: | Olmesartan Aurovitas 10 mg film-coated tablets EFG |
Italy: | Olmesartan medoxomil Aurobindo |
Portugal: | Olmesartan medoxomil Aurovitas |
Date of last revision of this leaflet: 01/2025
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) (http://www.aemps.gob.es/).
The average price of OLMESARTAN AUROVITAS 10 mg FILM-COATED TABLETS in October, 2025 is around 5.04 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for OLMESARTAN AUROVITAS 10 mg FILM-COATED TABLETS – subject to medical assessment and local rules.